957 filings
S-8
IMGN
Immunogen, Inc.
21 Dec 20
Registration of securities for employees
4:58pm
8-K
IMGN
Immunogen, Inc.
18 Dec 20
Entry into a Material Definitive Agreement
5:19pm
424B5
IMGN
Immunogen, Inc.
18 Dec 20
Prospectus supplement for primary offering
5:16pm
S-3ASR
IMGN
Immunogen, Inc.
18 Dec 20
Automatic shelf registration
4:45pm
8-K
IMGN
Immunogen, Inc.
18 Dec 20
Other Events
4:16pm
8-K
eqa6m5e8d8ocz626
11 Dec 20
Other Events
4:40pm
8-K
x22i7
7 Dec 20
ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting
8:02am
8-K
e4afi
6 Nov 20
ImmunoGen Reports Recent Progress and Third Quarter 2020 Financial Results
6:53am
8-K
zbxcb zzynpq
26 Oct 20
Departure of Directors or Certain Officers
9:22am
8-K
t5hf3k8mdl29v54v
19 Oct 20
ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China
8:57am
8-K
w5yslweuxhk9 2hi1ju
13 Oct 20
Other Events
8:11am
4
pjo2275p1cde kxnmyd7
1 Oct 20
ImmunoGen / Mark Alan Goldberg ownership change
2:39pm
4
jb1gv0boxcrv jvs2
1 Oct 20
ImmunoGen / DEAN J MITCHELL ownership change
2:38pm
8-K
lssyuswpbuoo3cnb8
25 Sep 20
Entry into a Material Definitive Agreement
4:38pm
424B5
bdey ts2h50nje
25 Sep 20
Prospectus supplement for primary offering
4:23pm
8-K
ltarp6 yu
31 Jul 20
ImmunoGen Reports Recent Progress and Second Quarter 2020 Financial Results
8:41am
8-K
k9tzso2wrwgtogj2g
22 Jul 20
ImmunoGen Appoints Susan Altschuller, PhD as Senior Vice President and Chief Financial Officer
4:10pm
4
2mghg of5
22 Jul 20
ImmunoGen / Susan ALTSCHULLER ownership change
3:44pm